Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

October 20, 2022

Study Completion Date

November 11, 2022

Conditions
Diabetes MellitusHemodialysis ComplicationCardiovascular ComplicationQuality of Life
Interventions
DEVICE

Tennant Biomodulator ®

Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.

Trial Locations (2)

3050

RECRUITING

Hamad Medical Corporation, Doha

77030

ACTIVE_NOT_RECRUITING

Baylor College of Medicine, USA, Houston

Sponsors
All Listed Sponsors
collaborator

Qatar National Research Fund

OTHER

collaborator

Baylor College of Medicine

OTHER

lead

Hamad Medical Corporation

INDUSTRY

NCT05407207 - Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility | Biotech Hunter | Biotech Hunter